Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05785845 · ClinicalTrials.gov registry record · NA

Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer

A NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer, sponsored by Washington University School of Medicine.

Active
Registry status
NA
Development phase
17
Enrollment target
1
Study location

NCT05785845 is a NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 17 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05785845, a NA study of Non-Small Cell Lung Cancer and Early Stage Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
17 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity. Online adaptive radiation therapy was until recently only done clinically on an integrated MRI-guided system, but recently, Varian Medical Systems has created a CT-guided radiotherapy machine capable of online adaptive radiotherapy (ETHOS). The vast majority of stereotactic body radiotherapy (SBRT) for early-stage lung cancers is performed on a CT-guided machine rather than an MRI-guided machine, necessitating the evaluation of adaptive radiotherapy using ETHOS in this population. Historically, the non-adaptive, stereotactic treatment of central and ultra-central thoracic disease has been associated with unacceptable rates of grade 3+ toxicity. This has resulted in widespread adoption of a hypofractionated, less ablative 8-15 day treatment courses, with a baseline, one-year grade 3+ toxicity rate of 20%. Use of CT-STAR with daily, CT-guided plan adaptation to carefully spare adjacent organs-at-risk (OAR) in this setting may enable safe delivery of a shorter (5 fraction) and more ablative radiotherapy course.

Interventions

  • RADIATION Computed tomography-guided stereotactic adaptive radiotherapy
  • DEVICE ETHOS

Study Locations (1)

Missouri

  • Washington University School of Medicine - St Louis

Trial Details

FieldValue
Enrollment Target 17 participants
Start Date 2023-04-10
Est. Completion 2026-07-28
Phase NA

What the Registry Record Tells You About NCT05785845

The ClinicalTrials.gov registry entry for NCT05785845 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (97% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Computed tomography-guided stereotactic adaptive radiotherapy is the first listed.

NCT05785845 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT05785845 about?

NCT05785845 is a clinical study titled "Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer". This study will evaluate the impact of CT-guided adaptive stereotactic radiotherapy (CT-STAR) to central and ultra-central early-stage non-small cell lung cancers on grade 3 or greater toxicity. Online adaptive radiation therapy was until recently only done clinically on an integrated MRI-guided sys...

What is the current status of trial NCT05785845?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 17 participants. The study started on 2023-04-10. Estimated completion is 2026-07-28.

What conditions does trial NCT05785845 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Early Stage Non-Small Cell Lung Cancer.

What interventions are being tested in trial NCT05785845?

The interventions under investigation include: Computed tomography-guided stereotactic adaptive radiotherapy (RADIATION), ETHOS (DEVICE).

Who is sponsoring clinical trial NCT05785845?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05785845 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.